{
  "@context": "aku-v2",
  "@type": "clinical-concept",
  "@id": "vascular:pharm:pharm-001-heparin",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-06T06:00:00.000Z",
    "last_updated": "2026-01-06T06:00:00.000Z",
    "contributors": [
      "copilot-agent",
      "knowledge-graph-agent"
    ],
    "confidence": 0.95,
    "status": "enhanced",
    "copyright_compliance": "Original content based on general medical knowledge",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/pharmacology",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "critical",
    "aku_id": "PHARM-001",
    "keywords": [
      "heparin",
      "anticoagulation",
      "UFH",
      "PTT",
      "protamine"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "anticoagulation",
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Unfractionated Heparin Pharmacology for Vascular Surgery",
    "statement": "Unfractionated Heparin Pharmacology for Vascular Surgery is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Pharmacology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Unfractionated Heparin Pharmacology for Vascular Surgery helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Unfractionated Heparin Pharmacology for Vascular Surgery include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Unfractionated Heparin Pharmacology for Vascular Surgery."
    },
    "pharmacology": {
      "mechanism": {
        "primary": "Potentiates antithrombin III (AT-III)",
        "targets": [
          "Factor IIa (thrombin)",
          "Factor Xa"
        ],
        "potentiation": "1000-fold increase in AT-III activity"
      },
      "pharmacokinetics": {
        "administration": "IV bolus and/or infusion",
        "onset": "Immediate (IV)",
        "half_life": "60-90 minutes (dose-dependent)",
        "elimination": "Hepatic, reticuloendothelial system"
      }
    },
    "intraoperative_use": {
      "dosing": {
        "standard": "80-100 units/kg IV bolus",
        "goal_act": "250-350 seconds (procedure dependent)",
        "redosing": "Every 45-60 minutes as needed"
      },
      "monitoring": {
        "act": "Point-of-care testing in OR",
        "goal": "Usually >250 seconds for vascular procedures"
      }
    },
    "therapeutic_anticoagulation": {
      "indications": [
        "DVT/PE treatment",
        "Postoperative anticoagulation",
        "Bridge therapy"
      ],
      "dosing": {
        "bolus": "80 units/kg",
        "infusion": "18 units/kg/hour",
        "adjustment": "Based on PTT every 6 hours until stable"
      },
      "monitoring": {
        "ptt": "Goal 60-80 seconds (or 1.5-2.5x baseline)",
        "anti_xa": "Alternative for heparin monitoring"
      }
    },
    "reversal": {
      "agent": "Protamine sulfate",
      "dose": "1 mg protamine per 100 units heparin given",
      "timing": "Account for heparin decay (half-life 60-90 min)",
      "administration": "Slow IV infusion (over 10 minutes)",
      "cautions": [
        "Hypotension (especially if given rapidly)",
        "Anaphylaxis (NPH insulin, fish allergy)",
        "Pulmonary vasoconstriction",
        "Paradoxical anticoagulation if excess given"
      ]
    },
    "complications": {
      "bleeding": {
        "risk": "Main complication",
        "management": "Hold heparin, protamine if severe"
      },
      "hit": {
        "type_1": {
          "onset": "Days 1-4",
          "mechanism": "Non-immune platelet aggregation",
          "severity": "Mild, transient, benign"
        },
        "type_2": {
          "onset": "Days 5-10 (or earlier if prior exposure)",
          "mechanism": "Immune-mediated, anti-PF4 antibodies",
          "severity": "Severe, thrombotic risk",
          "management": "Stop heparin, alternative anticoagulation (argatroban, bivalirudin)"
        }
      },
      "osteoporosis": "With long-term use"
    },
    "terminology": {
      "snomed_ct": "372877000",
      "icd_10": "Z79.01"
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Unfractionated Heparin"
    },
    "altLabel": [
      "UFH",
      "Heparin Sodium",
      "IV Heparin"
    ],
    "definition": {
      "@language": "en",
      "@value": "Anticoagulant that potentiates antithrombin III to inhibit thrombin and factor Xa, used for intraoperative and therapeutic anticoagulation."
    },
    "notation": "PHARM-001"
  },
  "clinical_features": {
    "presentation": [
      "Patient requiring anticoagulation for vascular procedure",
      "Patient with acute thrombosis (DVT, PE)",
      "Need for rapidly titratable anticoagulation"
    ],
    "diagnosis": [
      "Monitor PTT for therapeutic use",
      "Monitor ACT for intraoperative use",
      "HIT screening if platelet drop"
    ],
    "treatment": [
      "Weight-based dosing",
      "Monitoring and adjustment",
      "Protamine reversal as needed"
    ]
  },
  "relationships": {
    "prerequisites": [
      "vascular:coagulation:coagulation-cascade"
    ],
    "enables": [
      "vascular:procedures:vascular-surgery",
      "vascular:pharm:pharm-002-lmwh"
    ],
    "skos:broader": [
      "vascular:pharm:anticoagulation"
    ],
    "skos:related": [
      "vascular:pharm:pharm-006-reversal",
      "vascular:complications:hit"
    ],
    "skos:narrower": []
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Unfractionated Heparin Pharmacology for Vascular Surgery. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  },
  "pedagogical": {
    "target_audience": [
      "vascular surgery residents",
      "anesthesiology residents",
      "pharmacy students"
    ],
    "estimated_time": "15min",
    "learning_objectives": [
      "Explain the mechanism of heparin anticoagulation",
      "Calculate appropriate heparin dosing for vascular surgery",
      "Apply protamine reversal principles",
      "Recognize and manage heparin-induced thrombocytopenia"
    ],
    "clinical_pearls": [
      "Heparin dose: 80-100 units/kg for vascular procedures, goal ACT >250",
      "Protamine: 1 mg per 100 units heparin (give slowly to avoid hypotension)",
      "HIT Type II: Days 5-10, immune-mediated, thrombotic - STOP heparin",
      "Half-life 60-90 min - useful for short procedures without reversal",
      "Check PTT or ACT before redosing intraoperatively"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codeValue": "372877000",
      "codingSystem": "SNOMED-CT",
      "name": "Heparin"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "Z79.01",
      "codingSystem": "ICD-10-CM",
      "name": "Long term use of anticoagulants"
    }
  ]
}